Keqian Biology(SH:688526)2020-10-29 16:00Financial Performance - Net profit attributable to shareholders reached ¥319,739,673.87, up 67.48% year-on-year[18] - Operating income for the first nine months was ¥604,280,090.12, reflecting a 55.37% increase from the same period last year[18] - Basic earnings per share rose to ¥0.87, representing a 64.15% increase compared to the previous year[20] - The weighted average return on equity improved to 23.97%, an increase of 4.32 percentage points[20] - The company reported a net profit of ¥884,011,265.56 for the first three quarters of 2020, compared to ¥566,649,076.25 in the same period of 2019, representing an increase of approximately 55.9%[51] - Net profit for the first three quarters of 2020 reached CNY 135.45 million, up from CNY 35.61 million in 2019, indicating a growth of approximately 280%[64] Cash Flow - Net cash flow from operating activities increased by 183.09% to ¥358,922,241.68[18] - Cash flow from operating activities for the first three quarters of 2020 was CNY 632.25 million, compared to CNY 383.91 million in 2019, showing an increase of approximately 65%[66] - Cash inflow from financing activities amounted to $1.19 billion, with a net cash flow of $1.19 billion, contrasting with a net outflow of $85.75 million last year[73] Assets and Liabilities - Total assets increased to ¥3,024,316,354.94, a growth of 120.52% compared to the end of the previous year[18] - The total liabilities of the company as of September 30, 2020, are ¥443,862,520.99, compared to ¥252,477,161.39 in the previous year[43] - The company reported a total equity of ¥2,580,453,833.95 as of September 30, 2020, up from ¥1,118,981,322.58 in the previous year[43] - The total liabilities amounted to CNY 251,480,188.10, with current liabilities at CNY 206,309,286.51[86] Shareholder Information - The company reported a total of 19,550 shareholders at the end of the reporting period[22] - Major shareholder Wuhan Huazhong Agricultural Assets Management Co., Ltd. held 16.78% of shares, totaling 78,004,310 shares[22] Research and Development - Research and development expenses accounted for 6.75% of operating income, down 2.49 percentage points from the previous year[20] - The company obtained 32 new veterinary drug registration certificates, including 27 in collaboration with Huazhong Agricultural University[30] - The company is in the process of developing multiple new vaccines and diagnostic kits, with several projects in the new veterinary drug registration review stage[32] Revenue Growth - Total revenue for Q3 2020 reached ¥249,168,813.90, a significant increase from ¥102,222,090.40 in Q3 2019, representing a growth of approximately 144.3%[52] - The company reported a total revenue of CNY 612.02 million from sales and services in the first three quarters of 2020, compared to CNY 362.25 million in 2019, marking an increase of approximately 69%[66] Investment Activities - Total cash flow from investment activities resulted in a net outflow of CNY 745.80 million in 2020, compared to a net inflow of CNY 7.12 million in 2019[70] - The company has invested a total of ¥2,841,584.56 in the inactivated vaccine for Duck Tembusu virus (DF2 strain) and is currently in the new veterinary drug registration review stage[32] Market Expansion Plans - The company plans to continue expanding its market presence and investing in new product development to sustain growth in the upcoming quarters[61] - The company has plans for market expansion and new product development, although specific figures were not disclosed in the report[86]